HCP Connect Clinical Author
Dr. Meera Pillai
Oncology
Specialty
Oncology
Clinical Updates
25
Experience
7 Years
Author Biography
About Dr. Meera Pillai
Dr. Meera Pillai is a medical oncologist with 7 years of clinical experience. She completed a DM in Medical Oncology after an MD in General Medicine, focusing on breast and gynaecological cancers. She follows precision-oncology and antibody-drug-conjugate research closely. Her writing helps clinicians apply emerging cancer therapies responsibly.
Published Work
Recent Clinical Updates
25 articles
Oncology
FDA Approves Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma: 52% ORR
sonrotoclax mantle cell lymphoma approval: FDA accelerated approval for relapsed/refractory MCL with 52% ORR; 320 mg daily after 4-week ramp-up.
Oncology
FDA Approves relacorilant for Platinum-Resistant Ovarian Cancer; PFS HR 0.70 (ROSELLA)
relacorilant platinum-resistant ovarian cancer: FDA approves LIFYORLI with nab-paclitaxel after ROSELLA showed PFS HR 0.70 and OS benefit.
Oncology
Bispecific Antibodies in Oncology: Mechanisms and Approved Indications
Bispecific antibodies oncology: mechanisms, FDA‑approved indications, dosing, and safety for epcoritamab, glofitamab, elranatamab, linvoseltamab, and amivantamab.
Oncology
FDA Approves datopotamab deruxtecan for EGFR‑mutant NSCLC: 45% ORR
FDA approves datopotamab deruxtecan (DATROWAY) for EGFR‑mutated NSCLC after prior EGFR and platinum therapy; pooled ORR 45% and median DOR 6.5 months.
Oncology
FDA Approves Mirdametinib for NF1 PN: 41% ORR in Adults (ReNeu)
Mirdametinib approved for NF1 PN: ReNeu showed 41% ORR in adults and 52% in children; label: 2 mg/m2 twice daily, 21 days on/7 off.
Oncology
FDA Approves Telisotuzumab Vedotin for c‑Met High NSCLC: 35% ORR
Review of 2025 ADC evidence: telisotuzumab vedotin FDA approval in c‑Met high NSCLC (35% ORR), datopotamab deruxtecan PFS HR 0.63 in HR+ HER2‑ breast cancer, and ASCENT TNBC data.
Oncology
Vepdegestrant Approved for ESR1‑Mutant Breast Cancer; PFS HR 0.58
Vepdegestrant (VEPPANU) FDA approval for ESR1‑mutant breast cancer after endocrine therapy; VERITAC-2 showed PFS median 5.0 vs 2.1 months (HR 0.58) [1][11].
Oncology
FDA Approves T-DXd for HER2+ EBC: 67.3% pCR in DESTINY-Breast11
ENHERTU (trastuzumab deruxtecan) FDA neoadjuvant approval for HER2+ early breast cancer after DESTINY-Breast11 showed 67.3% pCR with T-DXd-THP.
Oncology
FDA Approves VEPPANU for ESR1‑Mutant Advanced Breast Cancer: PFS HR 0.57
VEPPANU approved for ESR1‑mutated advanced breast cancer; VERITAC‑2: PFS median 5.0 vs 2.1 months, HR 0.57. FDA-authorized ESR1 test required.
Oncology
FDA Approves LYNOZYFIC for Multiple Myeloma: 80% Response Rate in Relapsed Patients
FDA approves LYNOZYFIC for multiple myeloma: 80% response rate in relapsed patients, enhancing treatment options.
Medical Research
Remote Monitoring Cuts Cancer Surgery Recovery Time
Discover how remote perioperative monitoring improves outcomes for cancer surgery patients, reducing recovery time and enhancing care.
Oncology
Lipid Levels Linked to 30% Lower Lymphoma Risk
Discover how abnormal lipid levels impact lymphoid malignancy risk in a study of 403,625 UK Biobank participants with 10.5 years of follow-up.
Oncology
Targeting TMOD2 to Halt Colorectal Cancer Spread
Discover the crucial role of TMOD2 in colorectal cancer progression and metastasis, and how understanding its mechanisms can inform targeted treatment strategies for improved patie...
Oncology
ctDNA Guides Surgery for Recurrence
Learn how circulating tumor DNA can predict metastases and inform surgical decisions for better patient outcomes in oncology.
Oncology
82% Complete Response in BCG-Unresponsive NMIBC
Discover a new treatment option for high-risk BCG-unresponsive NMIBC, offering a complete response in 82% of patients and potentially reducing cystectomy rates.
Oncology
Detect MSI in CRC with 1-Hour Molecular Test
Quickly identify microsatellite instability-high colorectal cancer with a rapid molecular test, guiding targeted therapy decisions for patients.
Oncology
Similar Survival in ES-SCLC with Cis/Carbo Plus Etoposide
Real-world analysis shows comparable efficacy between cisplatin and carboplatin with etoposide in extensive-stage small cell lung cancer treatment.
Oncology
Improve Patient Outcomes with Early Palliative Care
Learn how early palliative care integration can enhance patient quality of life and reduce unnecessary hospitalizations in oncology practices
Medical Research
T Cell Exclusion Mechanisms in B Cell Lymphomas
Discover how ATR-dependent determinants exclude T cells from germinal center dark zones in aggressive B cell lymphomas, shedding light on lymphoma biology and potential therapeutic...
Medical Research
New Therapies May Reactivate Immune System in Resistant Melanoma
Researchers identify potential new strategies to overcome immunotherapy resistance in advanced melanoma, offering hope for improved patient outcomes.
Wellness
Inpatient Treatment Yields Better Outcomes for Dual Diagnosis
Learn how inpatient treatment can improve recovery outcomes for patients with dual diagnosis, prioritizing well-being and reducing recidivism rates effectively.
Healthcare Business
ACA Coverage Cuts Young Adult ED Visits by 30%
Discover how the Affordable Care Act's dependent coverage extension impacts substance-associated ED visits among young adults, reducing healthcare utilization and costs.
Healthcare Business
Cut NSCLC Resistance Rates by 30% with Dual Therapy
Learn how combining two therapies can reduce EGFR and MET resistance in NSCLC, improving treatment strategies and patient outcomes in second-line settings.
Oncology
48% Response Rate in ES-SCLC with Novel Therapy
Ifinatamab deruxtecan yields remarkable efficacy in extensive-stage small cell lung cancer, with a 48.2% overall response rate in previously treated patients.
Digital Health
AI Boosts Cardiac Cath Outcomes by 30%
Discover how AI-powered cardiac catheterization labs improve patient care and outcomes, enhancing interventional cardiology with advanced research and expertise.